Cas:432001-45-1 (3-Formyl-2-methyl-indol-1-yl)-acetic acid manufacturer & supplier

Chemical Name:(3-Formyl-2-methyl-indol-1-yl)-acetic acid

CAS.NO:432001-45-1

Synonyms:2-(3-formyl-2-methylindol-1-yl)acetic acid

Molecular Formula:C₁₂H₁₁NO₃

Molecular Weight:217.22100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:465.2ºC at 760 mmHg

Density:1.27g/cm3

Index of Refraction:1.609

PSA:59.30000

Exact Mass:217.07400

LogP:1.84680

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(3-formyl-2-methylindol-1-yl)acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(3-formyl-2-methylindol-1-yl)acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-formyl-2-methylindol-1-yl)acetic acid Use and application,2-(3-formyl-2-methylindol-1-yl)acetic acid technical grade,usp/ep/jp grade.

Related News: Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. (3-Formyl-2-methyl-indol-1-yl)-acetic acid manufacturer It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305. (3-Formyl-2-methyl-indol-1-yl)-acetic acid supplier What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. (3-Formyl-2-methyl-indol-1-yl)-acetic acid vendor The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. (3-Formyl-2-methyl-indol-1-yl)-acetic acid factory Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey.